Literature DB >> 33156563

The impact of type 2 diabetes on the development of tendinopathy.

Francesca Cannata1, Gianluca Vadalà2, Luca Ambrosio2, Nicola Napoli1, Rocco Papalia2, Vincenzo Denaro2, Paolo Pozzilli1.   

Abstract

Tendinopathy is a chronic and often painful condition affecting both professional athletes and sedentary subjects. It is a multi-etiological disorder caused by the interplay among overload, ageing, smoking, obesity (OB) and type 2 diabetes (T2D). Several studies have identified a strong association between tendinopathy and T2D, with increased risk of tendon pain, rupture and worse outcomes after tendon repair in patients with T2D. Moreover, consequent immobilization due to tendon disorder has a strong impact on diabetes management by reducing physical activity and worsening the quality of life. Multiple investigations have been performed to analyse the causal role of the individual metabolic factors occurring in T2D on the development of tendinopathy. Chronic hyperglycaemia, advanced glycation end-products, OB and insulin resistance have been shown to contribute to the development of diabetic tendinopathy. This review aims to explore the relationship between tendinopathy and T2D, in order to define the contribution of metabolic factors involved in the degenerative process and to discuss possible strategies for the clinical management of diabetic tendinopathy.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  advanced glycation end-products; hyperglycaemia; insulin resistance; obesity; tendinopathy; type 2 diabetes

Mesh:

Year:  2020        PMID: 33156563     DOI: 10.1002/dmrr.3417

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  1 in total

Review 1.  Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review.

Authors:  Annalisa Itro; Maria Consiglia Trotta; Roberta Miranda; Marco Paoletta; Annalisa De Cicco; Caterina Claudia Lepre; Umberto Tarantino; Michele D'Amico; Giuseppe Toro; Alfredo Schiavone Panni
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.